Takeda: Ulcer trials

The registry lists 56 Ulcer studies with Takeda as lead sponsor. 0 are open to participants now and 36 have results posted.

Phase 1 3Phase 2 7Phase 3 27Phase 4 7No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)CompletedNCT04873700Results posted
• A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's DiseaseCompletedNCT04804540Phase 4Results posted
• A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice in Ulcerative Colitis (UC) Korean ParticipantsCompletedNCT03535649Results posted
• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT03290781Phase 3Results posted
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)CompletedNCT03283085Phase 3Results posted
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative ColitisTerminatedNCT03259334Phase 3Results posted
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative ColitisTerminatedNCT03259308Phase 3Results posted
• Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"CompletedNCT03214952Results posted
• Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"CompletedNCT03214198Results posted
• Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use"CompletedNCT03214094Results posted
• Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)CompletedNCT03138655Phase 2Results posted
• Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori InfectionCompletedNCT03050359Phase 3Results posted
• Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori InfectionCompletedNCT03050307Phase 3Results posted
• Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative ColitisCompletedNCT03029143Phase 4Results posted
• Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's DiseaseTerminatedNCT02743806Phase 4Results posted
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's DiseaseCompletedNCT02620046Phase 3Results posted
• Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative ColitisCompletedNCT02611830Phase 3Results posted
• Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's DiseaseCompletedNCT02559713Phase 4Results posted
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative ColitisCompletedNCT02497469Phase 3Results posted
• Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]CompletedNCT02170207Results posted
• Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory DrugsCompletedNCT02099708Results posted
• Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose AspirinCompletedNCT02099682Results posted
• Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative ColitisCompletedNCT02093663Phase 3Results posted
• Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative ColitisCompletedNCT02039505Phase 3Results posted
• Long-Term Safety Of PF-00547659 In Ulcerative ColitisCompletedNCT01771809Phase 2Results posted
• A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative ColitisCompletedNCT01620255Phase 2Results posted
• Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFsCompletedNCT01387594Phase 1Results posted
• Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative ColitisCompletedNCT01130844Phase 1Results posted
• Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative ColitisCompletedNCT01124149Phase 4Results posted
• Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory DrugsCompletedNCT00787254Phase 3Results posted
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative ColitisCompletedNCT00783718Phase 3Results posted
• A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal UlcersTerminatedNCT00762359Phase 3Results posted
• Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's DiseaseCompletedNCT00619489Phase 2Results posted
• Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)CompletedNCT00446849Phase 4Results posted
• Evaluation of Safety and Activity of Celaderm in Healing Venous Leg UlcersCompletedNCT00399308Phase 1/2Results posted
• Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative ColitisCompletedNCT00151892Phase 3Results posted
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World PracticeCompletedNCT04890262
• A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real LifeTerminatedNCT03378388
• Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging MarketsCompletedNCT03090139
• A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD)CompletedNCT02986724
• Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's DiseaseWithdrawnNCT02913508Phase 2
• Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction StudyWithdrawnNCT02760615Phase 4
• Entyvio (Vedolizumab) Long Term Safety StudyCompletedNCT02674308
• A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin TherapyCompletedNCT01568398Phase 3
• A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) TherapyCompletedNCT01568385Phase 3
• Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)CompletedNCT01456260Phase 3
• Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose AspirinCompletedNCT01456247Phase 3
• Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose AspirinCompletedNCT01452763Phase 3
• Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)CompletedNCT01452750Phase 3
• Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal UlcerCompletedNCT01452724Phase 3
• Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric UlcerCompletedNCT01452711Phase 3
• Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative ColitisCompletedNCT00548574Phase 3
• Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476CompletedNCT00545389Phase 2
• Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative ColitisCompletedNCT00503243Phase 3
• A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose AspirinCompletedNCT00175032Phase 3
• Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.CompletedNCT00151944Phase 3